Hunan Jiudian Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 2.91%

Hunan Jiudian Pharmaceutical Co Ltd (300705) has an Asset Resilience Ratio of 2.91% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Hunan Jiudian Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥120.05 Million
≈ $17.57 Million USD Cash + Short-term Investments

Total Assets

CN¥4.12 Billion
≈ $602.85 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Hunan Jiudian Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Hunan Jiudian Pharmaceutical Co Ltd.

Liquid Assets Composition Over Time

This chart breaks down Hunan Jiudian Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Hunan Jiudian Pharmaceutical Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥120.05 Million 2.91%
Total Liquid Assets CN¥120.05 Million 2.91%

Asset Resilience Insights

  • Limited Liquidity: Hunan Jiudian Pharmaceutical Co Ltd maintains only 2.91% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Hunan Jiudian Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Hunan Jiudian Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Yunnan Baiyao Group Co Ltd
SHE:000538
Drug Manufacturers - Specialty & Generic 8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Harbin Gloria Pharmaceuticals
SHE:002437
Drug Manufacturers - Specialty & Generic 9.04%
Jiuzhitang Co Ltd
SHE:000989
Drug Manufacturers - Specialty & Generic 7.86%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%

Annual Asset Resilience Ratio for Hunan Jiudian Pharmaceutical Co Ltd (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Hunan Jiudian Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 4.01% CN¥161.29 Million
≈ $23.60 Million
CN¥4.02 Billion
≈ $588.08 Million
-3.72pp
2024-12-31 7.73% CN¥260.71 Million
≈ $38.15 Million
CN¥3.37 Billion
≈ $493.60 Million
+4.58pp
2023-12-31 3.14% CN¥90.29 Million
≈ $13.21 Million
CN¥2.87 Billion
≈ $420.15 Million
-0.78pp
2022-12-31 3.92% CN¥90.26 Million
≈ $13.21 Million
CN¥2.30 Billion
≈ $336.51 Million
-1.82pp
2021-12-31 5.75% CN¥100.31 Million
≈ $14.68 Million
CN¥1.75 Billion
≈ $255.38 Million
--
pp = percentage points

About Hunan Jiudian Pharmaceutical Co Ltd

SHE:300705 China Drug Manufacturers - Specialty & Generic
Market Cap
$772.35 Million
CN¥5.28 Billion CNY
Market Cap Rank
#10151 Global
#2701 in China
Share Price
CN¥10.55
Change (1 day)
+0.19%
52-Week Range
CN¥9.51 - CN¥17.57
All Time High
CN¥27.61
About

Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers chemical drug preparations, active pharmaceutical ingredients (APIs), pharmaceutical excipients, traditional Chinese medicine, health foods, and rehabilitation and wellness products. Its products portfolio includes loxoprofen sodium gel patches,… Read more